NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category (Descending) | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
70121-1569-07 | 70121-1569 | Filgrastim | RELEUKO | 300.0 ug/mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Feb. 25, 2022 | In Use | |
70121-1571-07 | 70121-1571 | Filgrastim | RELEUKO | 480.0 ug/1.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Feb. 25, 2022 | In Use | |
49884-0867-01 | 49884-0867 | Dronabinol | Dronabinol | 2.5 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 27, 2008 | In Use | |
49884-0867-02 | 49884-0867 | Dronabinol | Dronabinol | 2.5 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 30, 2008 | Jan. 31, 2020 | In Use |
49884-0867-05 | 49884-0867 | Dronabinol | Dronabinol | 2.5 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 27, 2008 | In Use | |
49884-0867-15 | 49884-0867 | Dronabinol | Dronabinol | 2.5 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 27, 2008 | In Use | |
49884-0868-01 | 49884-0868 | Dronabinol | Dronabinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 27, 2008 | In Use | |
49884-0868-02 | 49884-0868 | Dronabinol | Dronabinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 30, 2008 | Feb. 29, 2020 | In Use |
49884-0868-05 | 49884-0868 | Dronabinol | Dronabinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 27, 2008 | In Use | |
49884-0868-15 | 49884-0868 | Dronabinol | Dronabinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 27, 2008 | In Use | |
49884-0869-01 | 49884-0869 | Dronabinol | Dronabinol | 10.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 27, 2008 | In Use | |
49884-0869-02 | 49884-0869 | Dronabinol | Dronabinol | 10.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 30, 2008 | Feb. 29, 2020 | In Use |
49884-0869-05 | 49884-0869 | Dronabinol | Dronabinol | 10.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 27, 2008 | In Use | |
49884-0869-15 | 49884-0869 | Dronabinol | Dronabinol | 10.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | June 27, 2008 | In Use | |
45865-0598-10 | 45865-0598 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 3, 2015 | In Use | |
45865-0598-30 | 45865-0598 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sept. 3, 2015 | In Use | |
00078-0675-15 | 00078-0675 | ondansetron hydrochloride | ZOFRAN | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | March 7, 2018 | May 31, 2022 | No Longer Used |
00078-0676-15 | 00078-0676 | ondansetron hydrochloride | ZOFRAN | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec. 12, 2017 | May 31, 2022 | No Longer Used |
17478-0547-01 | 17478-0547 | Granisetron Hydrochloride | Granisetron Hydrochloride | 0.1 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Oct. 1, 2009 | In Use | |
51991-0065-97 | 51991-0065 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | May 1, 2020 | May 2, 2020 | No Longer Used | |
51991-0065-98 | 51991-0065 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Sept. 15, 2017 | May 31, 2022 | No Longer Used | |
68001-0366-25 | 68001-0366 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Oct. 5, 2018 | May 31, 2022 | No Longer Used | |
68001-0366-87 | 68001-0366 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Feb. 10, 2020 | Aug. 24, 2021 | No Longer Used | |
53097-0571-60 | 53097-0571 | Dronabinol | MARINOL | 2.5 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | March 3, 2021 | In Use | |
67457-0440-00 | 67457-0440 | Ondansetron | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Aug. 10, 2017 | In Use | |
67457-0440-22 | 67457-0440 | Ondansetron | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec. 29, 2014 | In Use | |
67877-0753-60 | 67877-0753 | Dronabinol | Dronabinol | 2.5 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | March 3, 2021 | In Use | |
67877-0754-60 | 67877-0754 | Dronabinol | Dronabinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | March 3, 2021 | In Use | |
67877-0755-60 | 67877-0755 | Dronabinol | Dronabinol | 10.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | March 3, 2021 | In Use | |
00006-0461-01 | 00006-0461 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | In Use | |
00006-0461-02 | 00006-0461 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | In Use | |
00006-0461-06 | 00006-0461 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | April 30, 2020 | In Use |
00006-0461-12 | 00006-0461 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | In Use | |
00006-0461-30 | 00006-0461 | Aprepitant | Emend | 80.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | March 26, 2003 | July 14, 2010 | In Use |
00006-3884-01 | 00006-3884 | Fosaprepitant Dimeglumine | Emend | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | July 8, 2010 | July 31, 2012 | No Longer Used | ||
00006-3884-32 | 00006-3884 | Fosaprepitant Dimeglumine | Emend | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Jan. 25, 2008 | July 31, 2012 | No Longer Used | ||
55513-0126-01 | 55513-0126 | Epoetin alfa | Epogen | 2000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | June 30, 1989 | In Use | ||
55513-0126-10 | 55513-0126 | Epoetin alfa | Epogen | 2000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | June 30, 1989 | In Use | ||
55513-0144-01 | 55513-0144 | Epoetin alfa | Epogen | 10000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug. 16, 1993 | In Use | ||
55513-0144-10 | 55513-0144 | Epoetin alfa | Epogen | 10000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug. 16, 1993 | In Use | ||
55513-0148-01 | 55513-0148 | Epoetin alfa | Epogen | 4000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug. 16, 1993 | In Use | ||
55513-0148-10 | 55513-0148 | Epoetin alfa | Epogen | 4000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug. 16, 1993 | In Use | ||
55513-0267-01 | 55513-0267 | Epoetin alfa | Epogen | 3000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | April 30, 1990 | In Use | ||
55513-0267-10 | 55513-0267 | Epoetin alfa | Epogen | 3000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | April 30, 1990 | In Use | ||
55513-0283-01 | 55513-0283 | Epoetin alfa | Epogen | 10000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Dec. 5, 1994 | In Use | ||
55513-0283-10 | 55513-0283 | Epoetin alfa | Epogen | 10000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Dec. 5, 1994 | In Use | ||
55513-0478-01 | 55513-0478 | Epoetin alfa | Epogen | 20000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | March 3, 1997 | In Use | ||
55513-0478-10 | 55513-0478 | Epoetin alfa | Epogen | 20000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | March 3, 1997 | In Use | ||
50090-1936-00 | 50090-1936 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | July 20, 2015 | In Use | |
50090-1936-01 | 50090-1936 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | July 20, 2015 | In Use |
Found 10,000 results in 5 milliseconds — Export these results